\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ was\\ given\\ thiamine\\,\\ but\\ expired\ \(0\)\
\-\ \\â\\€\\¢\\ t2\\ hyperintensity\\ within\\ the\\ both\\ thalami\ \(0\)\
\-\ \\â\\€\\¢\\ t2\\ hyperintensity\\ of\\ the\\ periaqueductal\\ grey\\ matter\ \(0\)\
\-\ \\â\\€\\¢\\ enhancement\\ of\\ both\\ mamillary\\ bodies\ \(0\)\
\-\ \\â\\€\\¢\\ enhancement\\ of\\ the\\ periaqueductal\\ grey\\ matter\ \(0\)\
\-\ wernicke\\ encephalopathy\ \(0\)\
\-\ \\â\\€\\¢\\ bilateral\\ thalamic\\ glioma\ \(1\)\
\-\ \\â\\€\\¢\\ metabolic\\/toxic\\ processes\\ \\(wernicke\\ encephalopathy\\,\\ leigh\\ disease\\,\\ wilson\\ disease\\)\ \(0\)\
\-\ \\â\\€\\¢\\ infectious\\ agents\\ \\(japanese\\ and\\ west\\ nile\\ encephalitis\\,\\ creutzfeldt\\-jakob\\ disease\\)\ \(0\)\
\-\ \\â\\€\\¢\\ vascular\\ lesions\\(deep\\ venous\\ thrombosis\\,\\ top\\ of\\ the\\ basilar\\ syndrome\\,\\ infarction\\ of\\ the\\ artery\\ of\\ percheron\\)\ \(0\)\
\-\ 52\\ year\\ old\\ woman\\ with\\ a\\ history\\ of\\ breast\\ cancer\\,\\ on\\ chemotherapy\\.\\ \\ poor\\ oral\\ intake\\ and\\ now\\ stuporous\\.\ \(0\)\
\-\ limited\\ differential\\ diagnosis\\ \\-\\ mr\\ imaging\\ is\\ the\\ modality\\ of\\ choice\\ differential\\ diagnosis\\ can\\ be\\ narrowed\\ by\\ the\\ imaging\\ appearance\\ in\\ combination\\ with\\ the\\ presence\\ or\\ absence\\ of\\ other\\ regions\\ of\\ involvement\\,\\ \\&\\ the\\ patient\\â\\€\\™s\\ history\\.\\ the\\ differential\\ includes\\ primary\\ neoplastic\\ processes\\ \\(bilateral\\ thalamic\\ glioma\\)\\,\\ metabolic\\/toxic\\ processes\\ \\(wernicke\\ encephalopathy\\,\\ leigh\\ disease\\,\\ wilson\\ disease\\)\\,\\ infectious\\ agents\\ \\(japanese\\ and\\ west\\ nile\\ encephalitis\\,\\ creutzfeldt\\-jakob\\ disease\\)\\,\\ \\&\\ vascular\\ lesions\\(deep\\ venous\\ thrombosis\\,\\ top\\ of\\ the\\ basilar\\ syndrome\\,\\ infarction\\ of\\ the\\ artery\\ of\\ percheron\\)\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ wernicke\\:\\ 0\\.2779599423357794\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.21223813737695485\ \(0\)\
\-\ periaqueductal\\:\\ 0\\.20525767831040004\ \(0\)\
\-\ percheron\\:\\ 0\\.19848372111680548\ \(0\)\
\-\ processes\\:\\ 0\\.19817970629277737\ \(0\)\
\-\ japanese\\:\\ 0\\.18893636468123462\ \(0\)\
\-\ nile\\:\\ 0\\.1821624074876401\ \(0\)\
\-\ leigh\\:\\ 0\\.17690811808494375\ \(0\)\
\-\ of\\:\\ 0\\.17085639079666734\ \(0\)\
\-\ disease\\:\\ 0\\.16914680698484724\ \(0\)\
\-\ west\\:\\ 0\\.16898531459468755\ \(0\)\
\-\ the\\:\\ 0\\.1608088297330491\ \(0\)\
\-\ thalamic\\:\\ 0\\.16058680445577833\ \(0\)\
\-\ wilson\\:\\ 0\\.15729587496936887\ \(0\)\
\-\ grey\\:\\ 0\\.14951978022930928\ \(0\)\
\-\ agents\\:\\ 0\\.14046816164583986\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.13394604298369264\ \(0\)\
\-\ encephalitis\\:\\ 0\\.13356928809438037\ \(0\)\
\-\ top\\:\\ 0\\.13108839793366037\ \(0\)\
\-\ differential\\:\\ 0\\.13091079194166594\ \(0\)\
\-\ basilar\\:\\ 0\\.12707733041782687\ \(0\)\
\-\ glioma\\:\\ 0\\.11410375372900211\ \(0\)\
\-\ thrombosis\\:\\ 0\\.1095127949017986\ \(0\)\
\-\ infectious\\:\\ 0\\.10807737291895633\ \(0\)\
\-\ stuporous\\:\\ 0\\.10740251737298545\ \(0\)\
\-\ infarction\\:\\ 0\\.10544505665287347\ \(0\)\
\-\ deep\\:\\ 0\\.10455639729343122\ \(0\)\
\-\ matter\\:\\ 0\\.10227255161508123\ \(0\)\
\-\ mamillary\\:\\ 0\\.09924186055840274\ \(0\)\
\-\ thiamine\\:\\ 0\\.09661471585705458\ \(0\)\
\-\ venous\\:\\ 0\\.09589770021730261\ \(0\)\
\-\ vascular\\:\\ 0\\.08867522130580244\ \(0\)\
\-\ artery\\:\\ 0\\.08342093190310608\ \(0\)\
\-\ syndrome\\:\\ 0\\.08097561074950248\ \(0\)\
\-\ expired\\:\\ 0\\.07864793748468443\ \(0\)\
\-\ enhancement\\:\\ 0\\.07731157468192829\ \(0\)\
\-\ t2\\:\\ 0\\.07727732496209545\ \(0\)\
\-\ lesions\\:\\ 0\\.07714082209730037\ \(0\)\
\-\ both\\:\\ 0\\.07490277149972188\ \(0\)\
\-\ thalami\\:\\ 0\\.07475989011465464\ \(0\)\
\-\ intake\\:\\ 0\\.07337319049366646\ \(0\)\
\-\ bilateral\\:\\ 0\\.07218789045612226\ \(0\)\
\-\ narrowed\\:\\ 0\\.07213274541330646\ \(0\)\
\-\ imaging\\:\\ 0\\.0705890856579698\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0696299243567504\ \(0\)\
\-\ modality\\:\\ 0\\.06641669725425396\ \(0\)\
\-\ choice\\:\\ 0\\.06368137409701767\ \(0\)\
\-\ combination\\:\\ 0\\.06232662385551903\ \(0\)\
\-\ 52\\:\\ 0\\.062199343274060875\ \(0\)\
\-\ neoplastic\\:\\ 0\\.06207342400833723\ \(0\)\
\-\ bodies\\:\\ 0\\.05881236467726361\ \(0\)\
\-\ regions\\:\\ 0\\.057638570299629675\ \(0\)\
\-\ poor\\:\\ 0\\.05665001740543769\ \(0\)\
\-\ oral\\:\\ 0\\.053788180432035114\ \(0\)\
\-\ limited\\:\\ 0\\.053603737926959986\ \(0\)\
\-\ absence\\:\\ 0\\.05354289366173918\ \(0\)\
\-\ includes\\:\\ 0\\.05222381823078734\ \(0\)\
\-\ history\\:\\ 0\\.05131756511941535\ \(0\)\
\-\ breast\\:\\ 0\\.04876921544395373\ \(0\)\
\-\ involvement\\:\\ 0\\.04860848476852229\ \(0\)\
\-\ presence\\:\\ 0\\.04825466831880059\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.04768762426135175\ \(0\)\
\-\ given\\:\\ 0\\.046198848926239836\ \(0\)\
\-\ now\\:\\ 0\\.04610168188955898\ \(0\)\
\-\ cancer\\:\\ 0\\.04473291576650408\ \(0\)\
\-\ patient\\:\\ 0\\.043687169244322116\ \(0\)\
\-\ mr\\:\\ 0\\.0434551996435676\ \(0\)\
\-\ and\\:\\ 0\\.04163300959362507\ \(0\)\
\-\ primary\\:\\ 0\\.04129579205354922\ \(0\)\
\-\ appearance\\:\\ 0\\.04048780537475124\ \(0\)\
\-\ can\\:\\ 0\\.03524313078607785\ \(0\)\
\-\ woman\\:\\ 0\\.034976840358960294\ \(0\)\
\-\ other\\:\\ 0\\.034876959894663495\ \(0\)\
\-\ but\\:\\ 0\\.03321043323324538\ \(0\)\
\-\ within\\:\\ 0\\.030931553329299814\ \(0\)\
\-\ by\\:\\ 0\\.028519780593226792\ \(0\)\
\-\ be\\:\\ 0\\.027243887784670674\ \(0\)\
\-\ with\\:\\ 0\\.026301304222993156\ \(0\)\
\-\ was\\:\\ 0\\.02340571932415939\ \(0\)\
\-\ or\\:\\ 0\\.023363562902730207\ \(0\)\
\-\ year\\:\\ 0\\.020697207932572268\ \(0\)\
\-\ on\\:\\ 0\\.020283294618654343\ \(0\)\
\-\ old\\:\\ 0\\.019876484131593996\ \(0\)\
\-\ is\\:\\ 0\\.018392060733442496\ \(0\)\
\-\ in\\:\\ 0\\.016707081630101008\ \(0\)\
